ArticleNature communications2017
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Network-based gene deletion analysis identifies candidate genes and molecular mechanism involved in clear cell renal cell carcinoma.Journal of genetics · 2021Pooled it
- A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2022Trial
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nature communications · 2021Trial
- NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability.iScience · 2026Article
- Disulfidptosis induced by intermittent fasting and metformin enhances the efficacy of anti-PD-1 therapy in renal cancer.Cell communication and signaling : CCS · 2026Article
- Deciphering genetic susceptibility to clear cell renal cell carcinoma.Communications biology · 2025Article
- Clinical value and mechanism of CDKN2A in clear cell renal cell carcinoma.Discover oncology · 2025Article
- Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer.Cancer discovery · 2025Article
- Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.Scientific reports · 2025Article
- A panel of three serum microRNAs as a potential diagnostic biomarker for renal cell carcinoma.Scientific reports · 2025Article
- Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis.Medical oncology (Northwood, London, England) · 2025Article
- Toward a CRISPR-based mouse model ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Contemporary review of papillary renal cell carcinoma-current state and future directions.Virchows Archiv : an international journal of pathology · 2024Review
- Bioprinted research models of urological malignancy.Exploration (Beijing, China) · 2024Review
- AURKB/CDC37 complex promotes clear cell renal cell carcinoma progression via phosphorylating MYC and constituting an AURKB/E2F1-positive feedforward loop.Cell death & disease · 2024Article
- Genetic study of thePractical laboratory medicine · 2024Article
- Molecular mechanisms and clinical relevance of endothelial cell cross-talk in clear cell renal cell carcinoma.Upsala journal of medical sciences · 2024Review
- Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma.International journal of molecular sciences · 2023Review
- Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.Nature cancer · 2023Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 6 institutions in 3 countries.
Sean T BaileyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Aleisha M SmithLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Jordan KardosLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Sara E WobkerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Harper L WilsonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Bhavani KrishnanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Ryoichi SaitoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Hyo Jin LeeDepartment of Internal Medicine, Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea.ORCID 0000-0001-8378-3001
Jing ZhangLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Samuel C EatonDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Lindsay A WilliamsLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Ujjawal ManochaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Dorien J PetersDepartment of Pathology, Leiden University Medical Center, Leiden 2333, The Netherlands.
Xinchao PanDepartments of Internal Medicine and Molecular Biology, UT Southwestern Medical Center, Dallas, Texas 75390, USA.
Thomas J CarrollDepartments of Internal Medicine and Molecular Biology, UT Southwestern Medical Center, Dallas, Texas 75390, USA.
Dean W FelsherDepartment of Medicine, Stanford University School of Medicine, Palo Alto, California 94305-5151, USA.
Vonn WalterDepartment of Biochemistry and Molecular Biology, Penn State Milton S. Hershey College of Medicine, 500 University Drive, Hershey, Pennsylvania 17033, USA.
Qing ZhangLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Jen Jen YehLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Richard A MoffittLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.ORCID 0000-0003-2723-5902
Janet Y LeungLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
William Y KimLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
University of North Carolina at Chapel Hill · USSouthwestern Medical Center · USChungnam National University · KRLeiden University Medical Center · NLPenn State Milton S. Hershey Medical Center · USStanford University · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3MUniversity of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7MUT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9MUNC Initiative for Maximizing Student DevelopmentR25GM055336 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN, KASH, THOMAS L. · 1996 to 2023
$12.1MNRSA IN GENETICST32GM007092 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SEKELSKY, JEFF J. · 1985 to 2019
$5.9MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MKinase Inhibition in Kidney CancerR01CA202053 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM, WILLIAM Y. · 2016 to 2020
$2.1MThe Therapeutic Potential of Targeting MYC Activity in Renal TumorigenesisR21CA194987 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEUNG, YEE MAN JANET (JANET) · 2015 to 2016
$359kNovel Method for Sample ProcessingR43CA120297 · NCI · ONE CELL SYSTEMS, INC · PI JIANG, YAJUAN · 2006 to 2006
$150kDiscovery of Molecular and Imaging Biomarkers in RCC patient-Derived TumorgraftsF31CA159897 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BAILEY, SEAN THOMAS · 2011 to 2013
$103kInvestigating HIF-MYC Interactions within a Clear Cell Renal Cell Carcinoma Murine ModelF31CA213985 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SMITH, ALEISHA MONIQUE · 2016 to 2018
$84kNCI NIH HHS F31 CA159897NCI NIH HHS F31 CA213985NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA202053NCI NIH HHS R21 CA194987NCI NIH HHS R43 CA120297NCI NIH HHS T32 CA071341NIDDK NIH HHS P30 DK079328NIEHS NIH HHS P30 ES010126NIGMS NIH HHS R25 GM055336NIGMS NIH HHS T32 GM007092
Abstract
Renal carcinoma is a common and aggressive malignancy whose histopathogenesis is incompletely understood and that is largely resistant to cytotoxic chemotherapy. We present two mouse models of kidney cancer that recapitulate the genomic alterations found in human papillary (pRCC) and clear cell RCC (ccRCC), the most common RCC subtypes. MYC activation results in highly penetrant pRCC tumours (MYC), while MYC activation, when combined with Vhl and Cdkn2a (Ink4a/Arf) deletion (VIM), produce kidney tumours that approximate human ccRCC. RNAseq of the mouse tumours demonstrate that MYC tumours resemble Type 2 pRCC, which are known to harbour MYC activation. Furthermore, VIM tumours more closely simulate human ccRCC. Based on their high penetrance, short latency, and histologic fidelity, these models of papillary and clear cell RCC should be significant contributions to the field of kidney cancer research.
Indexed as
Genes, mycADP-Ribosylation FactorsAnimalsCarcinoma, Renal CellCell Line, TumorCyclin-Dependent Kinase Inhibitor p16Gene Expression Regulation, NeoplasticHumansKidney NeoplasmsMice, KnockoutMice, TransgenicVon Hippel-Lindau Tumor Suppressor ProteinXenograft Model Antitumor AssaysADP-Ribosylation FactorsCyclin-Dependent Kinase Inhibitor p16VHL protein, mouseVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.